Turkey tail mushroom (Trametes versicolor) trials recruiting now
3 registrations that name turkey tail mushroom as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT06450873
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
Phase 2
Mayo Clinic
About 40 people
Started Oct 25, 2024
In plain words A Phase 2 study of turkey tail mushroom in female participants 18 and older, run by Mayo Clinic. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma.
Women ≥ 18 years of age
Histological confirmation of ER+, HER2- breast cancer, newly diagnosed and tissue available for central confirmation of Ki-67 measurement. Subjects are eligible if they have a Ki-67 of ≥10%.
Scheduled for definitive breast surgery
Detectable disease as defined by mammography, breast ultrasound of greater than 5mm in size.
15 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07195552
Clinical Trial: Rapid Immune Modulating Effects
No phase
Natural Immune Systems Inc
About 12 people
Started Jul 1, 2024
In plain words A study of turkey tail mushroom in people 18 to 75, run by Natural Immune Systems Inc. It plans to enroll about 12 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75; healthy volunteers accepted. Conditions: Immune Surveillance.
Healthy adults;
Age 18-75 years (inclusive);
Veins easy to see in one or both arms (to allow for the multiple blood draws);
Willing to comply with study procedures, including:
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Agaricus blazei; Reishi; Turkey Tail; Placebo
Registered summary
The goal for this clinical trial is to compare the immune effects of three different medicinal mushrooms to a placebo. The mushrooms include Agaricus, Reishi, and Turkey Tail.
Where, as registered
1 US site in 1 state.
RecruitingNCT04871412
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
Phase 3
Ottawa Hospital Research Institute
About 20 people
Started Apr 4, 2022
In plain words A Phase 3 study of turkey tail mushroom in people 18 and older, run by Ottawa Hospital Research Institute. It plans to enroll about 20 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Lung Cancer; Gastric Cancer; Esophageal Cancer.
Adults eligible for complete resection of lung, gastric or esophageal cancer
The exclusion criteria are on the listing.
What it tests, as registered
Vitamin D3 Drops; Coriolus Versicolor; Trident SAP 66:33 Lemon; Probiotic Pro12; Provitalix Pure Whey Protein; Theracurmin 2X; Green Tea Extract; Nutrition Recommendations; Physical Activity Recommendations; Psychological Recommendations
Registered summary
Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (\~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). The full summary is on the listing.
Where, as registered
No US site; Canada (2).
ClinicalTrials.gov lists 4 open registrations for this search, including ones where turkey tail mushroom is not a study arm or that are past the 3 we keep. Search them on ClinicalTrials.gov (opens in new tab).